Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) announced on Monday that it has entered into a definitive agreement to acquire Intra-Cellular Therapies Inc (Nasdaq:ITCI), a biopharmaceutical company focused on central nervous system (CNS) disorders, for USD132.00 per share in cash.

The acquisition includes CAPLYTA (lumateperone), approved for the treatment of schizophrenia and bipolar depression. The US Food and Drug Administration (FDA) is currently reviewing an application for CAPLYTA as an adjunctive treatment for major depressive disorder (MDD).

CAPLYTA has the potential to become a standard of care for most common depressive disorders and is expected to generate USD5bn+ in peak year sales. The deal also includes ITI-1284, a promising Phase 2 compound being studied in generalised anxiety disorder and Alzheimer's disease-related psychosis and agitation.

Subject to regulatory approvals and other customary closing conditions, the transaction is expected to close later this year.